Randomized phase II trial with irinotecan as monotherapy compared to irinotecan and bevacizumab (BevIri) for patients with platinum resistant non-resectable esophagus-, cardia or gastric cancer
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest